Financial Report: Lilly

Lilly
3Q Revenues: $5.7 billion (+9%)
3Q Earnings: $556 million (-29%)
YTD Revenues: $16.7 billion (+8%)
YTD Earnings: $1.5 billion (-26%)
Comments: Pharmaceutical revenue in the quarter grew 10%. New product revenue, composed of Trulicity, Basaglar, Taltz, Jardiance, Lartruvo, Cyramza, Olumiant and Portrazza, drove 14% volume growth and represented nearly 22% of total revenue. Trulicity revenue was $527.7 million, up 117%. Cyramza revenue was $196.0 million, up 23% Taltz sales were $151.3 million, an increase of $6.9 million compared with 2Q17. Basaglar sales were $145.7 million, an increase of $55.7 million. Jardiance sales were $127.2 million, up 168%. Humalog revenue increased 9% in the quarter to $696.2 million. Cialis sales were down 4% to $564.9 million due to decreased demand. Alimta sales were $514.5 million, down 10%. Forteo sales were $441.7 million, up 13% driven by higher realized prices. Humulin revenue was down 7% to $300.5 million driven by increased volume, partially offset by lower realized prices.